Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.63 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.51 |
| ▸ | KIF5B | P33176 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.50 |
| ▸ | LYN | P07948 | 1/20 | 0.50 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.50 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.50 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.50 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.50 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.50 |
| ▸ | ADK | P55263 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20695020 | 1.00 | EGFR (0.63) | EGFRKDREPHA2EPHB4FGFR1 | |
| SCHEMBL29786138 | 1.00 | EGFR (0.63) | EGFRKDREPHA2EPHB4FGFR1 | |
| SCHEMBL30777161 | 1.00 | EGFR (0.63) | EGFRKDREPHA2EPHB4FGFR1 | |
| SCHEMBL29904972 | 1.00 | EGFR (0.63) | EGFRKDREPHA2EPHB4FGFR1 | |
| SCHEMBL20695031 | 1.00 | EGFR (0.63) | EGFRKDREPHA2EPHB4FGFR1 | |
| SCHEMBL21481105 | 0.90 | EGFR (0.58) | EGFRKDREPHA2EPHB4FGFR1 | |
| SCHEMBL27040463 | 0.88 | EGFR (0.55) | EGFRKDREPHA2EPHB4RET | |
| SCHEMBL20695045 | 0.88 | EGFR (0.52) | EGFRKDREPHA2EPHB4FLT1 | |
| SCHEMBL20695040 | 0.88 | EGFR (0.52) | EGFRKDREPHA2EPHB4FLT1 | |
| SCHEMBL20695049 | 0.88 | EGFR (0.52) | EGFRKDREPHA2EPHB4FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4353715-B1 | 6-SUBSTITUTED CHIRALLY PURE DIFLUOROPIPERIDINE QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | WEISHANG SHANGHAI BIO PHARMACEUTICAL CO LTD (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-20250092015-A1 | A 6-substituted Chiral Pure Difluoropiperidine Quinazoline Derivative And Its Preparation Method | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2025-03-20 | — | — | US | disclosed |
| EP-4353715-A1 | 6-SUBSTITUTED CHIRALLY PURE DIFLUOROPIPERIDINE QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2024-04-17 | — | — | EP | disclosed |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | Wayshire Biopharm Holding Limited (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | Wayshire Biopharm Holding Limited (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2024016783-A1 | 6-SUBSTITUTED CHIRALLY PURE DIFLUOROPIPERIDINE QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | 威尚（上海）生物医药有限公司 | 2024-01-25 | — | — | WO | disclosed |
| CN-115260153-B | 6-substituted chiral pure difluoropiperidine quinazoline derivative and preparation method thereof | 威尚（上海）生物医药有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-115260153-A | 6-substituted chiral pure difluoropiperidine quinazoline derivative and preparation method thereof | 威尚（上海）生物医药有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-110357858-B | 5-substituted difluoropiperidine compounds having blood-brain barrier crossing capability | 威尚（上海）生物医药有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11168067-B2 | Substituted quinazoline compound having blood-brain barrier penetration capability | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-20200308140-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| US-20200308140-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| EP-3438107-B1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG SHANGHAI BIO PHARMACEUTICAL CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| EP-3438107-B1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG SHANGHAI BIO PHARMACEUTICAL CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| CN-108069946-B | Substituted quinazoline compounds having the ability to cross the blood brain barrier | 威尚（上海）生物医药有限公司 | 2020-06-05 | — | — | CN | disclosed |
| WO-2019196620-A1 | USAGE OF QUINAZOLINE COMPOUND AND AVASTIN IN PREPRARING COMBINED DISEASE-PREVENTING MEDICINE | 威尚（上海）生物医药有限公司 | 2019-10-17 | — | — | WO | disclosed |
| WO-2019196619-A1 | QUINAZOLINE DERIVATIVE SALT-FORM CRYSTAL FORM, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 威尚（上海）生物医药有限公司 | 2019-10-17 | — | — | WO | disclosed |
| WO-2019196621-A1 | USE OF QUINAZOLINE COMPOUND IN DRUG FOR TREATING CANCERS WITH EGFRV3 ACTIVATING MUTATION | 威尚（上海）生物医药有限公司 | 2019-10-17 | — | — | WO | disclosed |
| EP-3438107-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. (CN) | 2019-02-06 | — | — | EP | disclosed |
| EP-3438107-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. (CN) | 2019-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, FH | EGFR 1456/4885KDR 2106/4885EPHA2 4734/4885 |
| US-20200308140-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | KDR, FLT4, EGFR | EGFR 3/4885KDR 1/4885EPHA2 496/4885 |
| US-20250092015-A1 | A 6-substituted Chiral Pure Difluoropiperidine Quinazoline Derivative And Its Preparation Method | CYP2D6, QDPR, FDPS | EGFR 2446/4885KDR 2249/4885EPHA2 4172/4885 |
| US-11168067-B2 | Substituted quinazoline compound having blood-brain barrier penetration capability | KDR, FLT4, EGFR | EGFR 3/4885KDR 1/4885EPHA2 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.